Which words in Indications and Usage limit what a drug is for?

The qualifiers. 21 CFR 201.57 says that, when they apply, Indications and Usage must say a drug is indicated as an adjunct to a primary mode of therapy, describe the limits of its usefulness when evidence supports it only in selected subgroups, name tests needed to select or monitor patients, and say when it should be reserved for specific situations. Our view: those qualifiers carry the meaning, so a correctly spelled wrong word in one changes who the drug is for or how it's used. Spellcheck passes it.

This page is general information, not legal or regulatory advice.

For the other sections, see how to proofread a drug label for meaning, section by section. This page covers the qualifiers in the prescription section.

The qualifiers the rule names

21 CFR 201.57 lists the information this section must include when it applies:

• Adjunct use. If the drug is used only alongside a primary mode of therapy, a statement that it is indicated as an adjunct.
• Selected subgroups. If evidence supports use only in selected subgroups, a succinct description of the limits of usefulness.
• Tests. If specific tests are needed to select or monitor patients, what those tests are.
• Dosing limits. Limits that bear on dosing intervals, duration or dose changes, with a reference to Dosage and Administration.
• Reserved use. If safety calls for it, a statement that the drug should be reserved for specific situations.
• Long-term use. Conditions to meet before long-term use, or separate indications for long-term and short-term use.

Age groups and limitations of use

The FDA's draft guidance on this section, which is still a draft and not for implementation, recommends that indications include age groups, and it sets out when limitations of use belong in the section. It also suggests that when a drug reduces the risk of an outcome, wording such as reduce the risk of be considered rather than prevent, because prevent can imply more than the data support.

Our view: that is a word-choice point, and it shows how much a single verb carries in this section. A swapped group word or verb leaves a fluent indication that claims something else.

Highlights vs the full section

21 CFR 201.57 says Highlights must give a concise statement of each indication and briefly note major limitations of use. Our view: condensing is where qualifiers get dropped or swapped. Check that each qualifier in the full section survives in Highlights with the same meaning.

A live case in this section

We have a live case where an Indications line printed "indicted" where "indicated" belonged: indicted→indicated. For that pair on its own, see the pair explainer. The qualifiers above are just as easy to get wrong.

How to read the section for meaning

Practice advice:

• For each indication, say what it treats, in whom, and within what limits.
• Underline each qualifier and read it on its own: the group, the adjunct statement, the limitation.
• Check each qualifier against Highlights, and any dosing limit against Dosage and Administration. See wrong words in Dosage and Administration.
• For how Highlights relates to the full prescribing information, see PLR prescribing information wording.

This is our reading of public guidance, not legal or regulatory advice.

Sources

• eCFR: 21 CFR 201.57
• FDA draft guidance: Indications and Usage Section of Labeling for Human Prescription Drug and Biological Products — Content and Format (draft)

Last reviewed: October 18, 2026

More on contextual errors in FDA DailyMed labels.

Questions about wording on your own labels? Talk to us.

We scan freshly published FDA DailyMed labels every day and pull out these high-stakes wrong words.

Every Tuesday and Friday, a new case like this lands in your inbox if you subscribe.

What's in Indications and Usage?

21 CFR 201.57 says it must state what the drug is indicated for and, when they apply, qualifiers such as adjunct use, limits in selected subgroups, required tests and reserved use.

Which words in Indications and Usage matter most?

In our view: the qualifiers that limit use, such as the patient group, an adjunct statement and a limitation of use.

Is there FDA guidance on this section?

Yes, a draft. The FDA's draft guidance on Indications and Usage is still a draft and not for implementation; it recommends including age groups and covers limitations of use.

How do I check Indications and Usage for meaning?

Practice advice: for each indication, say what it treats, in whom and within what limits, then check each qualifier against Highlights.